Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
- Hospitalization for confirmed polymerase chain reaction (PCR) positive COVID-19 infection
- Active cancer, defined as a solid malignancy either undergoing active therapy, receiving therapy within 1 year, or a hematologic malignancy under active therapy or observation
- Patients with evidence of pulmonary involvement who meet any of the followings; presence of infiltrates on chest X-ray or computed tomography (CT) scan or need for supplemental oxygen < 8 L nasal cannula or pulse oximetry < 94% on room air
- Creatinine clearance >= 25 ml/min by Cockcroft-Gault equation
- Total bilirubin =< 1.5 x upper limit of normal (ULN) unless bilirubin rise is due to Gilbert’s syndrome or of non-hepatic origin
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
- Absolute neutrophil count (ANC) >= 1000/mm^3 independent of growth factor support
- Platelets >= 50,000/mm^3
- Ability to swallow capsules or receive opened capsule content via nasogastric or enteral feeding tube
- Ability to provide informed consent indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study. If a patient is unable to provide informed consent (e.g. does not possess decisional capacity), a legally authorized representative may provide consent for the patient
- Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug
- Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study
- Patients with new-onset malignancy requiring urgent initiation of systemic chemotherapy
- Active uncontrolled systemic bacterial or fungal infection
- Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon)
- Currently receiving BTK inhibitor therapy
- Actively receiving anti-cancer therapy (other than hormonal therapies). All anti-cancer therapy (except hormonal therapies) must be stopped at the time of screening; can be resumed as soon as ibrutinib is stopped. Significantly T cell suppressive chemotherapy (defined as requiring pneumocystis jiroveci pneumonia [PJP] prophylaxis per standard guidelines) is not allowed for 3 months prior to enrollment
- Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 (moderate) or class 4 (severe) cardiac disease as defined by the New York Heart Association Functional classification requirement for mechanical ventilation at screening
- Requirement for mechanical ventilation at screening
- Known bleeding disorders (e.g., Von Willebrand’s disease, platelet storage pool disorders, or hemophilia)
- Stroke or intracranial hemorrhage within 6 months of screening
- Major surgery or non-healing wound within 4 weeks of enrollment
- Concomitant administration of prohibited medications
- Known history of human immunodeficiency virus (HIV), or active hepatitis B or C infection
- Disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption (malabsorption syndrome, resection of the small bowel, poorly controlled inflammatory bowel disease, etc.)
- Requires chronic treatment with strong CYP3A inhibitors or inducers
- Participation in another clinical trial for COVID 19 (antiviral based trials accepting co-enrollment, compassionate or emergency use or expanded access protocols are allowed)
I. To determine the feasibility and tolerability of administering ibrutinib in COVID-19 infected patients. (Safety Run-In)
II. To determine whether ibrutinib administration plus standard care for COVID-19 (Arm A) in cancer patients can diminish respiratory failure or death as compared to untreated control population receiving placebo plus standard therapy (antiviral such as remdesivir or others, chloroquine, hydroxychloroquine, cytokine blocking peptides or small molecules) (Arm B). (Phase II)
I. To determine time to clinical resolution of need for supplemental oxygen (i.e. maintenance of oxygen saturation of 93% or greater on room air with ambulation) or need for supplemental oxygen above baseline for those on home oxygen.
II. To determine rate of intensive care unit (ICU) admission and length of ICU admission for patients treated with ibrutinib (Arm A) versus control population receiving standard therapy (Arm B).
III. To determine rate of shock requiring vasopressor support for patients treated with ibrutinib (Arm A) versus control population receiving standard therapy (Arm B).
IV. To determine the rate of secondary infection (bacterial, fungal, viral) for patients treated with ibrutinib (Arm A) versus control population receiving standard therapy (Arm B).
V. To determine the time to hospital discharge for patients treated with ibrutinib (Arm A) versus control population receiving standard therapy (Arm B).
VI. To determine grade 3 or higher toxicity observed in patients treated with ibrutinib (Arm A) versus control population receiving standard therapy (Arm B).
VII. To determine time to mechanical ventilation, the number of days of mechanical ventilation per patient and total observed in patients treated with ibrutinib (Arm A) versus control population receiving standard therapy (Arm B).
VIII. To determine the overall survival at 3 and 12 months post-enrollment.
I. To determine the time to defervescence (oral temperature < 100.5 degrees Fahrenheit [F] for a 48 hour time period) among patients treated with ibrutinib (Arm A) versus control population receiving standard (Arm B) therapy.
II. To examine the impact of baseline clinical features (e.g. type of cancer, active therapy), duration of symptoms prior to admission and laboratory features (e.g. T cell count) on outcome for patients treated on this therapeutic study.
III. To determine the proportion of patients with viral clearance at end of ibrutinib therapy, time of hospital discharge and follow up thereafter among patients treated with ibrutinib (Arm A) versus control (Arm B) treatment.
IV. To determine the time and proportion of patients who develop immunoglobulin (Ig)M and IgG levels toward SARS-coronavirus (CoV)-2 treated with ibrutinib (Arm A) versus control treatment (Arm B).
V. To examine immune cell subsets for absolute number, activation, exhaustion markers, and presence of maturation arrest (natural killer [NK] cells) at baseline and over time among patients treated with ibrutinib (Arm A) versus control (Arm B) treatment.
VI. To examine T-cell repertoire over time among patients treated with ibrutinib (Arm A) versus control (Arm B) treatment.
VII. To determine the influence of epigenetic age, clonal hematopoiesis, and monoclonal B cell lymphocytosis (MBL) on treatment outcome.
VIII. To determine serial change in inflammatory markers as CRP, ferritin, D-dimer and cytokines including IL6, IL1B, and TNF-alpha serum levels over time among patients treated with ibrutinib (Arm A) versus control (Arm B) treatment.
OUTLINE: This is a phase Ib, dose-escalation study followed by a phase II study. Patients are randomized to 1 of 2 arms.
ARM A: Patients receive ibrutinib orally (PO) once daily (QD) on days 1-7. Treatment repeats every 7 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients who remain hospitalized or are re-admitted after 2 cycles may receive an additional 2 cycles per physician’s discretion.
ARM B: Patients receive usual care. Patients who meet the requirement of mechanical ventilation may cross-over to Arm A.
After completion of study treatment, patients are followed up for up to 12 months.
Trial Phase Phase I/II
Trial Type Treatment
Ohio State University Comprehensive Cancer Center
Jennifer Ann Woyach
- Primary ID OSU-20135
- Secondary IDs NCI-2020-03341, 2020C0107
- Clinicaltrials.gov ID NCT04439006